How Fortrea Mobile Clinical Services (MCS) may improve the patient experience in oncology studies

Case Study highlights Fortea mobile clinical support services in global oncology trials to support investigator sites and patients.

Hybrid protocol: Accelerated success

Efficient FIH hybrid protocol trial design for a biotechnology immunology drug study.

Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2026

The Fortrea team has over 60 oncologists, many often contribute to oncology peer-reviewed journal articles. Read the articles here.

Is it time to go beyond classic design in oncology trials?

This paper discusses how FIH studies with healthy volunteers could open up new possibilities in cancer drug development.

A new era of the clinical trial: How immuno-oncology advances are reshaping traditional clinical development paradigms

Reviewing recent advancements in oncology clinical trial design and execution, and exploring challenges and opportunities for effective patient therapies.

Combining multiple therapies for metastatic breast cancer ADCs and ICIs

Review of how ADCs and ICIs combined use can significantly improve outcomes in patients with metastatic breast cancer.

Chimeric antigen receptor T-cell publication spotlight: our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing CAR-T drug development

CAR-T cell therapies represent a breakthrough. Read Fortrea's oncology team contributions to CAR-T peer-reviewed journal articles in this information sheet.

Antibody-drug conjugate publication spotlight: our top three recent peer-reviewed journal articles featuring Fortrea oncologists discussing ADC drug development

Antibody-drug conjugates are an exciting advance in cancer therapeutics. Read about Fortrea's oncology team contributions to ADC peer-reviewed journal articles.

The importance of early integration of liquid biopsy to enhance oncology research

Pricing and reimbursement in Germany: At a glance